United Therapeutics Corporation
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2008 | $-40.4M | $-164.8M | $124.4M | $28.7M |
| FY2009 | $99.7M | $4.3M | $95.4M | $101.0M |
| FY2010 | $211.5M | $192.9M | $18.6M | $113.9M |
| FY2011 | $250.2M | $214.2M | $36.0M | $-15.7M |
| FY2012 | $323.6M | $211.7M | $111.9M | $30.1M |
| FY2013 | $425.3M | $393.4M | $31.9M | $320.8M |
| FY2014 | $355.3M | $307.9M | $47.4M | $190.1M |
| FY2015 | $382.8M | $333.0M | $49.8M | $280.3M |
| FY2016 | $643.6M | $605.6M | $38.0M | $12.1M |
| FY2017 | $474.2M | $387.9M | $86.3M | $73.5M |
| FY2018 | $778.4M | $594.0M | $184.4M | $-26.4M |
| FY2019 | $-206.6M | $-290.3M | $83.7M | $45.4M |
| FY2020 | $755.7M | $696.4M | $59.3M | $163.8M |
| FY2021 | $598.2M | $477.4M | $120.8M | $138.5M |
| FY2022 | $802.5M | $663.7M | $138.8M | $106.8M |
| FY2023 | $978.0M | $747.6M | $230.4M | $39.1M |
| FY2024 | $1.33B | $1.08B | $246.5M | $144.0M |
| FY2025 | $1.56B | $1.04B | $520.5M | $147.7M |